$216.12▾ 5.51%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
+66.9%year over year
Strong
Revenue is growing strongly year over year.
Leverage
Not enough data yet
Term-debt data is not available for this company.
More coming: dilution / share-count creep.
Fair value
Overvalued
Trading about 46% above our fair-value range
Value-trap risk
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
Alnylam Pharmaceuticals, Inc.'s earnings-quality signal is not available yet. Revenue is growing strongly year over year.
Key numbers
Valuation
EPS (TTM)$5.37
TTM (trailing 12 months, through fiscal Q2 FY2026)
Profitability
Net margin15.3%
TTM (trailing 12 months, through fiscal Q2 FY2026)
Size
Revenue (TTM)$4.80B
TTM (trailing 12 months, through fiscal Q2 FY2026)
Recent news
Sentiment · last 30 days5 articles
2 bullish0 neutral3 bearish
ALNYLAM INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Alnylam Pharmaceuticals, Inc. on Behalf of Alnylam Stockholders and Encourages Investors to Contact the Firm
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
ALNYLAM PHARMACEUTICALS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
Atlas Healthcare Fund by VST Capital Entered Eli Lilly at $350 in 2020 — The Stock Now Trades Above $1,200
Oligonucleotide CDMO Market to Reach USD 9.87 Billion by 2031 as RNA-Targeted Drug Pipelines Expand
Signals and key numbers are from the fiscal Q2 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.